Paradigm Biopharmaceuticals (PAR.AX) Action Cours

Paradigm Biopharmaceuticals Ltd develops injectable pentosan polysulfate sodium (iPPS/PPS) under the brand Zilosul for treating osteoarthritis, mucopolysaccharidoses (MPS), alphavirus-induced arthralgia, chronic heart failure, and acute respiratory distress syndrome. The company focuses on PPS, a semi-synthetic drug derived from European beech wood chips, which mimics glycosaminoglycans (GAGs) and clears GAG accumulation while inhibiting MMP-3 synthesis. Paradigm sells Zilosul to healthcare providers and hospitals for patient treatment, targeting segments with osteoarthritis, MPS, and viral arthritis conditions. The company's revenue comes from the sale of Zilosul, which addresses multiple therapeutic areas including joint pain, mobility issues, and cartilage degradation. The biopharmaceutical company's primary product Zilosul is used for osteoarthritis treatment, with additional applications in MPS, Ross River virus, and Chikungunya-related joint pain. PPS works by clearing cellular GAG buildup and blocking MMP-3, a protein that degrades cartilage. Paradigm generates income through the direct sale of Zilosul to medical institutions for patient care, focusing on chronic conditions like osteoarthritis and viral arthritis. The company's revenue streams are tied to the prescription and administration of Zilosul across these medical segments. Paradigm Biopharmaceuticals Ltd markets Zilosul as a therapeutic solution for osteoarthritis, MPS, and alphavirus-induced arthralgia. The product is sold to healthcare facilities where it is administered to patients with joint pain, mobility limitations, and cartilage damage. Revenue is generated through the sale of Zilosul, which treats multiple conditions including chronic heart failure and acute respiratory distress syndrome. The company's business model centers on developing and selling PPS-based treatments for specific medical needs without additional product lines.